Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. - Wikidata - wikimedia - TriplyDB

Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.

Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.

http://www.wikidata.org/entity/Q44117619

about

Therapy-related acute promyelocytic leukemia Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.Therapy-related acute promyelocytic leukemia: a systematic review.Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.Molecular pathogenesis of secondary acute promyelocytic leukemia Acute myeloid leukemia developing in patients with autoimmune diseases.Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.Treatment related acute promyelocytic leukemia (t-APML) in breast cancer survivor treated with anthracycline based chemotherapy: rare case report.Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice CD34(+) therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer.Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.The evolving challenge of therapy-related myeloid neoplasms.Acute leukemia in women.Therapy-related acute promyelocytic leukemia in plasma cell myeloma treated with melphalan: a case report and literature review Acute promyelocytic leukemia with a smoldering course associated with therapy-related myelodysplastic syndrome.Bleeding and thrombosis in acute promyelocytic leukemia.DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes.Topoisomerase-mediated chromosomal break repair: an emerging player in many games.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia.All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma.Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience.Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma.Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL)

P2860

Q24629042-48D3D276-C294-46ED-ACE3-DE8CE6B36871 Q27012691-7CB3F6CB-9B77-4809-A544-27FA9B78F06D Q33435191-618D0EF1-A2F9-402F-A9E2-8614995B2E18 Q33597526-5FB2BC29-4308-479B-8355-90C690B32812 Q34198047-CE1DC144-7953-44E8-B040-ECCA535B077B Q34227027-756DFD25-102F-4C06-A2C9-51F7C19C5FC4 Q34351253-3F073AF9-2B88-4607-AC04-6CCAFF820AE9 Q34750640-8888F350-B656-4DD2-AD31-7FB91ED9D92E Q34870833-A59B30DF-F1AE-4EB5-A9E6-98B280658158 Q35560260-F81D46B0-838D-4328-916B-0A24257767EF Q36006358-E5F96A8B-2420-4E85-8E2E-A4D083DEFCF4 Q36335336-A0A32CBE-6733-47EE-BC2C-A820E3587DDC Q36566275-34A533BA-BCDE-43F9-8BAF-33C2DBBFE232 Q36835079-424699F9-D2DF-4613-AA69-4950BC25F777 Q37044055-732A98F8-45FB-40EC-A4AA-EB1B11370B7B Q37346340-28BBDC8E-8C1E-4484-A934-4CCDF3E94FA4 Q37576054-ACB32534-11BD-4FA5-8A26-DA9330522BF3 Q37699362-D92F8CB9-59B3-4D7F-B616-EF49F55A70B3 Q37740419-BA9C95E4-2464-4BA2-8B8B-CCA57A8F9E48 Q37901284-4B87E658-1DFE-41F5-ABDF-B62E8EF5D521 Q38006876-BF3AE973-6852-4E95-8D9A-A45E5EB61422 Q38052129-E508E8F3-D46A-48FE-870F-C8BDBDD3505F Q38309335-4F05EF24-CCBC-45B2-90E7-EE627AA7456B Q38360744-9A6C6B11-1828-47A5-90DB-1F1C6E28B4A9 Q38542828-97C4558F-1FF8-49BF-8113-041B08DA3AD1 Q38891536-183BAD9B-7724-4B9B-B5F4-88187AF677C0 Q41662169-C962112F-F626-4744-907F-D3D46B1A43B7 Q41906202-F0136546-814D-4023-85FB-9E21AEA97F02 Q42196299-228E1668-2318-49B6-817E-DEE98979FAE1 Q43084094-ADF239DD-39AC-4F10-ABB1-15252067BCBB Q43115838-4F3AE591-D777-4E21-8DE1-8A18F11B7BA9 Q44433813-6F1D8147-6069-4709-B8D4-D54379A4C7A1 Q44808153-46381917-7059-4785-8BCA-9CF4F2FF6E6A Q45951577-D1F3154E-ECCD-455E-9CFC-EF04D3CE428F Q47414654-6AC77A28-52F1-4F11-9061-7C32F48A979F Q53554112-4CF2A336-984F-4563-8305-236BB161A0C7 Q57224260-E3D7BE83-1B14-466F-BE4C-3B0C5D91C664

P2860

Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.

http://www.wikidata.org/entity/Q44117619

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Clinicobiological features and ...... tumor: the GIMEMA experience.

@en

Clinicobiological features and ...... tumor: the GIMEMA experience.

@nl

type

label

Clinicobiological features and ...... tumor: the GIMEMA experience.

@en

Clinicobiological features and ...... tumor: the GIMEMA experience.

@nl

prefLabel

Clinicobiological features and ...... tumor: the GIMEMA experience.

@en

Clinicobiological features and ...... tumor: the GIMEMA experience.

@nl

P1433

Q44117619-070A90A1-E9B5-46A3-8132-563507AD1266

P1476

Q44117619-50C1FD72-E5C3-4BA5-868A-E7BB21EE2196

P2093

Q44117619-0273BF24-CF95-4AB7-9D4B-049522DE3A69

Q44117619-07FB8705-EC85-4F59-B924-216C270C0EA9

Q44117619-1A30142F-77F2-4EB3-B604-114A29132BAD

Q44117619-1F6D1C2C-4167-451F-9456-70C8C0B53D49

Q44117619-245EAEB4-A632-4D4E-9E93-59E49C0AF4A6

Q44117619-2DE6B51F-721E-4CBA-9E28-B87815512D5D

Q44117619-6A80F5AD-7D57-4FD8-8D19-0D7456545CCA

Q44117619-731A3E42-440C-494A-8B35-4F535F9D9F6B

Q44117619-8B54B168-637D-4918-80DA-30C723092E15

Q44117619-8EB9C0FE-85C8-47EF-94DA-53CD2E3D8392

P304

Q44117619-20BC6428-DCC6-45F6-97AE-68BB02110E1A

P31

Q44117619-C6F558A6-1E92-4035-A00F-07742A9195F1

P356

Q44117619-46A8288B-2E53-4817-8FD5-88D4CDE13C86

P407

Q44117619-05472FC1-1C14-457C-AE49-3A4179D05ED5

P433

Q44117619-FEAB19BE-30D4-4129-A31D-41D0ED04FDBF

P478

Q44117619-322B3724-FAD9-4BDE-AEFB-ED0592DAB297

P50

Q44117619-4F3DA517-9D82-455C-B191-8B24614280E6

Q44117619-73949A4D-D780-44C2-83CE-B5E7B68EE06C

Q44117619-9DF511BF-C4C4-4EF2-A2CF-695EECB0F518

P577

Q44117619-7831EA5D-4DC7-424A-B392-6E55B6D604D3

P5875

Q44117619-A32D4DB0-1552-4C47-81A1-331806843356

P698

Q44117619-E9161B39-49E7-49A6-A3CA-8B22F50E750C

P921

Q44117619-CD42B692-E9F1-4943-83AD-037333695C0C

P356

BLOOD-2001-12-0312

P1433

P1476

Clinicobiological features and ...... tumor: the GIMEMA experience.

@en

P2093

Alessandro Pulsoni

http://www.w3.org/2001/XMLSchema#string

Alfonso Mele

http://www.w3.org/2001/XMLSchema#string

Anna Maria Nosari

http://www.w3.org/2001/XMLSchema#string

Enrico Maria Pogliani

http://www.w3.org/2001/XMLSchema#string

Eros Di Bona

http://www.w3.org/2001/XMLSchema#string

Filippo Marmont

http://www.w3.org/2001/XMLSchema#string

Franco Leoni

http://www.w3.org/2001/XMLSchema#string

Franco Mandelli

http://www.w3.org/2001/XMLSchema#string

Giuseppe Visani

http://www.w3.org/2001/XMLSchema#string

Livio Pagano

http://www.w3.org/2001/XMLSchema#string

P304

1972-1976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2001-12-0312

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Avvisati

Francesco Lo Coco

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11188779

http://www.w3.org/2001/XMLSchema#string

P698

12200354

http://www.w3.org/2001/XMLSchema#string

P921